Shore Capital reissued their hold rating on shares of Smith & Nephew plc (LON:SN) in a research report report published on Friday, May 5th. They currently have a GBX 1,144 ($14.77) price objective on the stock.
A number of other analysts have also weighed in on SN. Morgan Stanley reaffirmed an overweight rating on shares of Smith & Nephew plc in a research note on Wednesday, January 11th. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a GBX 1,260 ($16.26) price objective on shares of Smith & Nephew plc in a research report on Thursday, January 12th. Berenberg Bank reaffirmed a hold rating and issued a GBX 1,340 ($17.30) price objective on shares of Smith & Nephew plc in a research report on Wednesday, January 18th. Deutsche Bank AG reaffirmed a hold rating and issued a GBX 1,150 ($14.84) price objective on shares of Smith & Nephew plc in a research report on Monday, February 6th. Finally, Credit Suisse Group AG reaffirmed a neutral rating and issued a GBX 1,190 ($15.36) price objective on shares of Smith & Nephew plc in a research report on Wednesday, February 8th. Ten analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of GBX 1,279.58 ($16.52).
Smith & Nephew plc (LON:SN) traded up 1.14% during midday trading on Friday, reaching GBX 1327.00. 3,181,526 shares of the company’s stock traded hands. Smith & Nephew plc has a 52-week low of GBX 1,064.91 and a 52-week high of GBX 1,340.00. The company’s 50-day moving average price is GBX 1,268.37 and its 200-day moving average price is GBX 1,204.72. The stock’s market cap is GBX 11.60 billion.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/05/20/smith-nephew-plc-sn-earns-hold-rating-from-shore-capital-updated.html.
In other news, insider Olivier Bohuon sold 8,031 shares of the firm’s stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of GBX 1,222 ($15.77), for a total value of £98,138.82 ($126,679.77).
About Smith & Nephew plc
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.